Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods:: results from a population-based study of young breast cancer patients

被引:18
|
作者
Lee, Eunjung [1 ]
McKean-Cowdin, Roberta [1 ]
Ma, Huiyan [2 ]
Chen, Zhengjia [1 ,3 ]
Van Den Berg, David [1 ]
Henderson, Brian E. [1 ]
Bernstein, Leslie [4 ,5 ]
Ursin, Giske [1 ,6 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA
[2] Univ So Calif, Keck Sch Med, Inst Hlth Promot & Dis Prevent Res, Alhambra, CA 91803 USA
[3] Childrens Oncol Grp, Arcadia, CA 91066 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
[6] Univ Oslo, Dept Nutr, N-0316 Oslo, Norway
来源
BREAST CANCER RESEARCH | 2008年 / 10卷 / 01期
关键词
D O I
10.1186/bcr1865
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Efforts are ongoing to determine the significance of unclassified variants ( UVs) in the breast cancer susceptibility genes BRCA1/ BRCA2, but no study has systematically assessed whether women carrying the suspected deleterious UVs have characteristics commonly seen among women carrying known deleterious or disease- causing mutations in BRCA1/ BRCA2. Methods We sequenced BRCA1/ BRCA2 in 1,469 population-based female breast cancer patients diagnosed between the ages of 20 and 49 years. We used existing literature to classify variants into known deleterious mutations, polymorphic variants, and UVs. The UVs were further classified as high risk or low risk based on five methods: allele frequency, Polyphen algorithm, sequence conservation, Grantham matrix scores, and a combination of the Grantham matrix score and sequence conservation. Furthermore, we examined whether patients who carry the variants classified as high risk using these methods have risk characteristics similar to patients with known deleterious BRCA1/ BRCA2 mutations ( early age at diagnosis, family history of breast cancer or ovarian cancer, and negative estrogen receptor/ progesterone receptor). Results We identified 262 distinct BRCA1/ BRCA2 variants, including 147 UVs, in our study population. The BRCA1 UV carriers, but not the BRCA2 UV carriers, who were classified as high risk using each classification method were more similar to the deleterious mutation carriers with respect to family history than those carriers classified as low risk. For example, the odds ratio of having a first- degree family history for the high- risk women classified using Polyphen was 3.39 ( 95% confidence interval = 1.16 to 9.94) compared with normal/ polymorphic BRCA1 carriers. The corresponding odds ratio of low- risk women was 1.53 ( 95% confidence interval = 1.07 to 2.18). The odds ratio for high- risk women defined by allele frequency was 2.00 ( 95% confidence interval = 1.14 to 3.51), and that of low-risk women was 1.30 ( 95% confidence interval = 0.87 to 1.93). Conclusion The results suggest that the five classification methods yielded similar results. Polyphen was particularly better at isolating BRCA1 UV carriers likely to have a family history of breast cancer or ovarian cancer, and may therefore help to classify BRCA1 UVs. Our study suggests that these methods may not be as successful in classifying BRCA2 UVs.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer
    Wen-Ming Cao
    Yun Gao
    Hong-Jian Yang
    Shang-Nao Xie
    Xiao-Wen Ding
    Zhi-Wen Pan
    Wei-Wu Ye
    Xiao-Jia Wang
    BMC Cancer, 16
  • [32] Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes
    Narod, Steven A.
    Rodriguez, Adriana A.
    SALUD PUBLICA DE MEXICO, 2011, 53 (05): : 420 - 429
  • [33] Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
    Gabai-Kapara, Efrat
    Lahad, Amnon
    Kaufman, Bella
    Friedman, Eitan
    Segev, Shlomo
    Renbaum, Paul
    Beeri, Rachel
    Gal, Moran
    Grinshpun-Cohen, Julia
    Djemal, Karen
    Mandell, Jessica B.
    Lee, Ming K.
    Beller, Uziel
    Catane, Raphael
    King, Mary-Claire
    Levy-Lahad, Ephrat
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (39) : 14205 - 14210
  • [34] Genes beyond BRCA1 and BRCA2 for hereditary breast cancer
    Simon, Katharina
    Geigl, Jochen B.
    Pristauz, Gunda
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2010, 160 (19-20) : 478 - 482
  • [35] Haplotype analysis of BRCA1/BRCA2 variants in Korean patients with breast cancer
    Kwon, Won Kyung
    Jang, Hyeok-Jae
    Jang, Ja-Hyun
    Lee, Jeong Eon
    Park, Yeon Hee
    Kim, Jong-Won
    GENETIC EPIDEMIOLOGY, 2020, 44 (05) : 489 - 490
  • [36] CLINICOPATHOLOGICAL CHARACTERISTICS AND BRCA1 /BRCA2 PATHOGENIC VARIANTS OF PATIENTS WITH BREAST CANCER
    Eras, Nazan
    Tuncel, Ferah
    Altintas, Zuhal
    Erden, Sema
    POLISH JOURNAL OF PATHOLOGY, 2024, 75 (01) : 1 - 7
  • [37] Re:: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients
    Chappuis, PO
    Hamel, N
    Paradis, AJ
    Deschênes, J
    Tonin, PN
    Ghadirian, P
    Foulkes, WD
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (02) : 152 - 153
  • [38] Turkish population-based screening for first identified changes of BRCA1 and BRCA2 genes in breast and/or ovarian cancer patients
    Sevimli, Tugba Semerci
    Sevimli, Murat
    Manguoglu, Ayse Esra
    Luleci, Guven
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2024, 25 (01)
  • [39] Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
    Parmigiani, G
    Berry, DA
    Aguilar, O
    AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (01) : 145 - 158
  • [40] Breast cancer genetics.: BRCA1 and BRCA2:: The main susceptibility genes.
    Ruiz-Flores, P
    Calderón-Garcidueñas, AL
    Barrera-Saldaña, HA
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2001, 53 (01): : 46 - 64